GGBa

NVIDIA has announced Halos for Robotics, a full-stack safety system for robotics and physical AI that extends the company's autonomous vehicle safety architecture to machines operating alongside people in factories, warehouses and logistics operations. Tw

Fribourg-based LS Instruments has been acquired by Postnova Analytics, with operations and its team remaining in Fribourg.

Best Of Getting Serious… So Far! A compilation of highlights from the first year of Getting Serious, gathering conversations with neuroscientists, entrepreneurs, commodity traders, and festival directors on what makes Switzerland work as a place to build

AB2 Bio, based at the EPFL Innovation Park in Lausanne, has received a USD 30 million payment after Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States. The company is eligible for up to USD 100 million in development

Hilo has closed a USD 19 million Series B extension and launched Hilo Core, its blood pressure monitoring system, in the United States.

Actival, a spin-off of CSEM, has been awarded a CHF 1.4 million grant from Innosuisse to accelerate the development and market launch of its patented Active Splints, a new generation of patient-specific oral care devices developed in partnership with CSEM

Two start-ups based at the Biopôle life sciences campus in Lausanne, MoleSense and Impli, have been selected by the German Federal Agency for Breakthrough Innovation (SPRIN-D) for its Challenge on continuous hormone monitoring. Support includes funding of

Immitra Bio has completed an upsized pre-seed financing round of CHF 2.4 million. CHF 2.25 million came from venture capital and private investors, with a further CHF 150,000 secured through non-dilutive funding. The round was led by Backbone Ventures and

HeroSupport has announced that NYU Grossman School of Medicine is the first clinical site in the United States to participate in its SHIELD clinical study, with Prof. Naamit Gerber as principal investigator. Prof. Gerber is a professor and vice chair of e

Pilatus Biosciences, which develops metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, has received the Certificate for Clinical Trial / Medicinal Test from the Hong Kong Department of Health for its lead investigational therapy,